More than 10 years of IFN-free HCV treatment and viral hepatitis elimination: Mission not completed! [0.03%]
无IFN丙肝治疗和病毒性肝炎消除超过十年：使命尚未完成！
Niklas Luhmann,Heiner Wedemeyer
Niklas Luhmann
Deceased donor liver utilisation and assessment: Consensus guidelines from the European Liver and Intestine Transplant Association [0.03%]
欧洲肝肠移植协会关于供体肝脏利用和评估的共识指导意见
Amelia J Hessheimer,Hermien Hartog,Francesca Marcon et al.
Amelia J Hessheimer et al.
Over the past two decades, the application of machine perfusion (MP) in human liver transplantation has moved from the realm of clinical exploration to routine clinical practice. Both in situ and ex situ perfusion strategies are feasible, s...
Practice Guideline
Journal of hepatology. 2025 Apr 3:S0168-8278(25)00092-3. DOI:10.1016/j.jhep.2025.01.042 2025
Cisplatin-induced Disruption of Mitochondrial Divisome Leads to Enhanced Cisplatin Resistance in Cholangiocarcinoma [0.03%]
顺铂诱导的线粒体分裂体紊乱可增强胆管癌顺铂耐药性
Guo-Yue Lv,Wen-Tao Mu,Yan-Nan Cao et al.
Guo-Yue Lv et al.
Background & aims: Cisplatin (CDDP)-based chemotherapy is the primary treatment for advanced cholangiocarcinoma (CCA), but its clinical efficacy is limited. Mitochondrial divisome (MD) is crucial for regulating mitochondr...
Thyroid Function and MASLD Risk Stratification in Children with Obesity: a not negligible link [0.03%]
肥胖儿童甲状腺功能与MASLD风险分层：一个不可忽略的联系
Anna Di Sessa,Gianmario Forcina,Giuseppina Rosaria Umano et al.
Anna Di Sessa et al.
Sumeet K Asrani,Patrick S Kamath,Pere Gines
Sumeet K Asrani
Maria Buti,Mar Riveiro-Barciela,Xavier Forns
Maria Buti
European Association for the Study of the Liver
European Association for the Study of the Liver
Transjugular intrahepatic portosystemic shunt (TIPS) placement is a well-established procedure for managing complications of portal hypertension. In recent years, the field of TIPS has seen rapid advances, particularly in technical approach...
Practice Guideline
Journal of hepatology. 2025 Apr 1:S0168-8278(25)00066-2. DOI:10.1016/j.jhep.2025.01.029 2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study [0.03%]
晚期胆道癌患者在KEYNOTE-966随机三期研究中的健康相关生活质量
Changhoon Yoo,Makoto Ueno,Heinz-Josef Klümpen et al.
Changhoon Yoo et al.
Background & aims: In the randomized, double-blind, phase 3 KEYNOTE-966 trial, pembrolizumab plus gemcitabine and cisplatin demonstrated a significant improvement in overall survival as first-line therapy for advanced bil...
eIF3f promotes tumour malignancy by remodelling fatty acid biosynthesis in hepatocellular carcinoma [0.03%]
eIF3f通过重塑肝细胞癌中的脂肪酸生物合成促进肿瘤恶性程度提升
Suiqing Zhou,Liren Zhang,Yue You et al.
Suiqing Zhou et al.
Background & aims: Fatty acid metabolism is closely associated with hepatocellular carcinoma (HCC). Elucidating the molecules that influence fatty acid metabolism in HCC is important for developing precise therapy. Howeve...
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials [0.03%]
脂质体伊立替康治疗先前接受过治疗的胆道癌患者：NIFTY和NALIRICC试验的综合分析
Changhoon Yoo,Anna Saborowski,Jaewon Hyung et al.
Changhoon Yoo et al.
Background & aim: Liposomal irinotecan (nal-IRI) combined with fluorouracil (5-FU)/leucovorin (LV) as a second-line treatment for biliary tract cancer (BTC) following progression on gemcitabine-based therapy in the Korean...